

Kenneth E Sherman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2662713/publications.pdf>

Version: 2024-02-01

143
papers

6,831
citations

109137

35
h-index

62479

80
g-index

148
all docs

148
docs citations

148
times ranked

5847
citing authors

#	ARTICLE	IF	CITATIONS
1	One-Year Outcomes of the Multi-Center Study to Transplant Hepatitis C-Infected kidneys (MYTHIC) Trial. <i>Kidney International Reports</i> , 2022, 7, 241-250.	0.4	12
2	A review of alcohol–pathogen interactions: New insights into combined disease pathomechanisms. <i>Alcoholism: Clinical and Experimental Research</i> , 2022, 46, 359-370.	1.4	9
3	Cocaine, simultaneous alcohol and cocaine use, and liver fibrosis in people living with and without HIV. <i>Drug and Alcohol Dependence</i> , 2022, 232, 109273.	1.6	5
4	Impact of Prior Drug Allergies on the Risk, Clinical Features, and Outcomes of Idiosyncratic Drug-Induced Liver Injury in Adults. <i>Digestive Diseases and Sciences</i> , 2022, 67, 5262-5271.	1.1	4
5	Long-term Follow-up of Hepatitis C Patients Who Achieved Sustained Virologic Response in the Pragmatic PRIORITIZE Study. <i>Clinical Gastroenterology and Hepatology</i> , 2022, , .	2.4	0
6	Viral hepatitis in pregnancy. <i>Journal of Viral Hepatitis</i> , 2022, 29, 844-861.	1.0	5
7	Cognitive Impairment among People Who Use Heroin and Fentanyl: Findings from the Miami Adult Studies on HIV (MASH) Cohort. <i>Journal of Psychoactive Drugs</i> , 2021, 53, 215-223.	1.0	6
8	The Enhanced Liver Fibrosis Index Predicts Hepatic Fibrosis Superior to FIB4 and APRI in HIV/HCV Infected Patients. <i>Clinical Infectious Diseases</i> , 2021, 73, 450-459.	2.9	10
9	Sustained Virologic Response of Patients Hospitalized Compared With Those Not Hospitalized During Treatment for Hepatitis C Virus With Direct-Acting Antivirals. <i>Annals of Pharmacotherapy</i> , 2021, 55, 565-574.	0.9	0
10	Food insecurity is associated with magnetic resonance–determined nonalcoholic fatty liver and liver fibrosis in low-income, middle-aged adults with and without HIV. <i>American Journal of Clinical Nutrition</i> , 2021, 113, 593-601.	2.2	19
11	Food Insecurity and Cognitive Impairment in the Miami Adult Studies on HIV (MASH) Cohort. <i>Journal of Nutrition</i> , 2021, 151, 979-986.	1.3	3
12	PNPLA3 Single Nucleotide Polymorphism Prevalence and Association with Liver Disease in a Diverse Cohort of Persons Living with HIV. <i>Biology</i> , 2021, 10, 242.	1.3	3
13	Heroin use is associated with liver fibrosis in the Miami Adult Studies on HIV (MASH) cohort. <i>Drug and Alcohol Dependence</i> , 2021, 220, 108531.	1.6	11
14	The synthetic opioid fentanyl enhances viral replication in vitro. <i>PLoS ONE</i> , 2021, 16, e0249581.	1.1	5
15	Hepatitis E Infection in a Longitudinal Cohort of HCV and HCV/HIV Coinfected Persons. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 534-541.	0.5	2
16	Soluble CD163 Identifies Those at Risk for Increased Hepatic Inflammation & Fibrosis. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab203.	0.4	7
17	Immune Activation: A Link Between Food Insecurity and Chronic Disease in People Living With Human Immunodeficiency Virus. <i>Journal of Infectious Diseases</i> , 2021, 224, 2043-2052.	1.9	1
18	Pulmonary Vascular Resistance Predicts Mortality and Graft Failure in Transplantation Patients With Portopulmonary Hypertension. <i>Liver Transplantation</i> , 2021, 27, 1811-1823.	1.3	16

#	ARTICLE	IF	CITATIONS
19	A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study. <i>Hepatology</i> , 2021, 74, 2952-2964.	3.6	7
20	CCR5+ T-Cells Homed to the Liver Exhibit Inflammatory and Profibrogenic Signatures in Chronic HIV/HCV-Coinfected Patients. <i>Viruses</i> , 2021, 13, 2074.	1.5	1
21	Incorporating Patientsâ€™ Values and Preferences Into Decision Making About Transplantation of HCV-Naïve Recipients With Kidneys From HCV-Viremic Donors: A Feasibility Study. <i>MDM Policy and Practice</i> , 2021, 6, 238146832110565.	0.5	1
22	Validation and Refinement of Noninvasive Methods to Assess Hepatic Fibrosis: Magnetic Resonance Elastography Versus Enhanced Liver Fibrosis Index. <i>Digestive Diseases and Sciences</i> , 2020, 65, 1252-1257.	1.1	7
23	Sex Differences, Cocaine Use, and Liver Fibrosis Among African Americans in the Miami Adult Studies on HIV Cohort. <i>Journal of Women's Health</i> , 2020, 29, 1176-1183.	1.5	8
24	Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2678-2687.	3.0	55
25	Hepatitis C Virus Cure Is the Start of the End for Patients With Advanced Fibrosis/Cirrhosis. <i>Clinical Infectious Diseases</i> , 2020, 71, 2730-2731.	2.9	1
26	Treatment of HCV reduces viral hepatitis-associated liver-related mortality in patients: An ERCHIVES study. <i>Journal of Hepatology</i> , 2020, 73, 277-284.	1.8	29
27	Safety and Efficacy of Budesonide for Liver Transplant Immune Suppression: Results of a Pilot Phase 2a Trial. <i>Liver Transplantation</i> , 2020, 26, 1430-1440.	1.3	3
28	Cost-effectiveness of Using Kidneys From HCV-Viremic Donors for Transplantation Into HCV-Uninfected Recipients. <i>American Journal of Kidney Diseases</i> , 2020, 75, 857-867.	2.1	26
29	CCR5 receptor antagonism inhibits hepatitis C virus (HCV) replication in vitro. <i>PLoS ONE</i> , 2019, 14, e0224523.	1.1	13
30	Hepatitis B Vaccination and Waning Hepatitis B Immunity in Persons Living with HIV. <i>Current HIV/AIDS Reports</i> , 2019, 16, 395-403.	1.1	25
31	In response to identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients. <i>Journal of Hepatology</i> , 2019, 71, 1259-1260.	1.8	3
32	Cost Effectiveness of Universal Screening for Hepatitis C Virus Infection in the Era of Direct-Acting, Pangenotypic Treatment Regimens. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 930-939.e9.	2.4	70
33	Use of HCV Ab+/NAT- donors in HCV naïve renal transplant recipients to expand the kidney donor pool. <i>Clinical Transplantation</i> , 2019, 33, e13598.	0.8	21
34	Zika virus replication and cytopathic effects in liver cells. <i>PLoS ONE</i> , 2019, 14, e0214016.	1.1	26
35	Association of TIMP1 Levels and Liver Disease Progression Among HIV/HCV Co-infected, HIV Mono-, HCV Mono-infected, and Healthy Groups from the MASH Cohort (FS09-07-19). <i>Current Developments in Nutrition</i> , 2019, 3, nzz044.FS09-07-19.	0.1	0
36	Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: An integrated analysis of 7 phase III studies. <i>Drug and Alcohol Dependence</i> , 2019, 194, 487-494.	1.6	33

#	ARTICLE	IF	CITATIONS
37	Improvement in Hepatic Fibrosis Biomarkers Associated With Chemokine Receptor Inactivation Through Mutation or Therapeutic Blockade. <i>Clinical Infectious Diseases</i> , 2019, 68, 1911-1918.	2.9	17
38	HBV and HIV/HBV Infected Patients Have Distinct Immune Exhaustion and Apoptotic Serum Biomarker Profiles. <i>Pathogens and Immunity</i> , 2019, 4, 39.	1.4	16
39	Hepatitis C virus cure with direct-acting antivirals: Clinical, economic, societal and patient value for China. <i>World Journal of Hepatology</i> , 2019, 11, 442-449.	0.8	5
40	Fatty liver disease in persons with HIV infection. <i>Topics in Antiviral Medicine</i> , 2019, 27, 75-82.	0.1	16
41	HIV and the liver. <i>Topics in Antiviral Medicine</i> , 2019, 27, 101-110.	0.1	10
42	Pre-vaccine plasma levels of soluble inflammatory indices negatively predict responses to HAV, HBV, and tetanus vaccines in HCV and HIV infection. <i>Vaccine</i> , 2018, 36, 453-460.	1.7	19
43	Viral Hepatitis: Knowledge and Treatments for Hepatitis B and C Virus and Associated Transplantation and Neoplasia. <i>Gastroenterology</i> , 2018, 154, 453-456.	0.6	2
44	Ultra-Deep Genomic Sequencing of HCV NS5A Resistance-Associated Substitutions in HCV/HIV Coinfected Patients. <i>Digestive Diseases and Sciences</i> , 2018, 63, 645-652.	1.1	1
45	Hepatitis D diagnostics: Utilization and testing in the United States. <i>Virus Research</i> , 2018, 250, 114-117.	1.1	42
46	HIV and the Liver. , 2018, , 536-555.e7.		1
47	A changing paradigm: management and treatment of the HCV/HIV-co-infected patient. <i>Hepatology International</i> , 2018, 12, 500-509.	1.9	17
48	PNPLA3 Gene Polymorphisms in HCV/HIV-Coinfected Individuals. <i>Digestive Diseases and Sciences</i> , 2018, 63, 2969-2974.	1.1	4
49	Zika Virus Exposure in an HIV-Infected Cohort in Ghana. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, e35-e38.	0.9	9
50	Hepatitis B virus (HBV) reactivation—The potential role of direct-acting agents for hepatitis C virus (HCV). <i>Reviews in Medical Virology</i> , 2018, 28, e1984.	3.9	17
51	Transplanting organs from hepatitis B positive donors: Is it safe? Is it ethical?. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1110-1115.	1.0	6
52	CD56 ^{bright} NK IL-7R ^{hi} expression negatively associates with HCV level, and IL-7-induced NK function is impaired during HCV and HIV infections. <i>Journal of Leukocyte Biology</i> , 2017, 102, 171-184.	1.5	18
53	Characterization of HCV NS3 Protease Variants in HCV/HIV-Coinfected Patients by Ultra-Deep Sequence Analysis: Relationship with Hepatic Fibrosis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 74, 353-358.	0.9	1
54	Hepatitis delta and HIV infection. <i>Aids</i> , 2017, 31, 875-884.	1.0	35

#	ARTICLE	IF	CITATIONS
55	Underutilization of Hepatitis D Virus Testing Among HBV Monoinfected and HBV/HIV Coinfected Patients. <i>Gastroenterology</i> , 2017, 152, S162.	0.6	1
56	Human immunodeficiency virus and liver disease: A comprehensive update. <i>Hepatology Communications</i> , 2017, 1, 987-1001.	2.0	29
57	Phase 3 trial of first generation protease inhibitor therapy for hepatitis C virus/human immunodeficiency virus coinfection. <i>World Journal of Hepatology</i> , 2017, 9, 217.	0.8	2
58	The Enigma of Hepatitis E Virus. <i>Gastroenterology and Hepatology</i> , 2017, 13, 484-491.	0.2	11
59	Cocaine Use and Liver Disease are Associated with All-Cause Mortality in the Miami Adult Studies in HIV (MASH) Cohort. <i>Journal of Drug Abuse</i> , 2016, 02, .	0.2	9
60	Sofosbuvir-based regimens in clinical practice achieve SVR rates closer to clinical trials: results from ARCHIVES. <i>Liver International</i> , 2016, 36, 651-658.	1.9	33
61	HCV Council "critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape. <i>Liver International</i> , 2016, 36, 488-502.	1.9	4
62	Association between IL28B rs12979860 single nucleotide polymorphism and the frequency of colonic Treg in chronically HCV-infected patients. <i>Archives of Virology</i> , 2016, 161, 3161-3169.	0.9	23
63	Evaluating the Role of Cellular Immune Responses in the Emergence of HCV NS3 Resistance Mutations During Protease Inhibitor Therapy. <i>Viral Immunology</i> , 2016, 29, 252-258.	0.6	9
64	Recombination among GB virus C (GBV-C) isolates in the United States. <i>Journal of General Virology</i> , 2016, 97, 1537-1544.	1.3	11
65	Extra-hepatic infection of hepatitis C virus in the colon tissue and its relationship with hepatitis C virus pathogenesis. <i>Journal of Medical Microbiology</i> , 2016, 65, 703-712.	0.7	17
66	Human immunodeficiency virus and liver disease: An update. <i>Hepatology</i> , 2015, 62, 1871-1882.	3.6	37
67	Association of colonic regulatory T cells with hepatitis C virus pathogenesis and liver pathology. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1543-1551.	1.4	27
68	Extrahepatic Manifestations of Hepatitis C Infection: Navigating CHASM. <i>Current HIV/AIDS Reports</i> , 2015, 12, 353-361.	1.1	35
69	Liver Fibrosis Progression in Hepatitis C Virus Infection After Seroconversion. <i>JAMA Internal Medicine</i> , 2015, 175, 178.	2.6	71
70	Epidemiology of Hepatitis C Virus. <i>Gastroenterology Clinics of North America</i> , 2015, 44, 699-716.	1.0	30
71	Management of the Hepatitis B Virus/HIV-Coinfected Patient. <i>Topics in Antiviral Medicine</i> , 2015, 23, 111-4.	0.1	4
72	HCV treatment of special populations: HIV coinfecting, liver transplant, and renal failure. <i>Clinical Liver Disease</i> , 2014, 4, 80-83.	1.0	2

#	ARTICLE	IF	CITATIONS
73	Modulation of HCV replication after combination antiretroviral therapy in HCV/HIV co-infected patients. <i>Science Translational Medicine</i> , 2014, 6, 246ra98.	5.8	19
74	Evidence of distinct populations of hepatitis C virus in the liver and plasma of patients co-infected with HIV and HCV. <i>Journal of Medical Virology</i> , 2014, 86, 1332-1341.	2.5	7
75	Direct-Acting Antiviral Agents and the Path to Interferon Independence. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 728-737.	2.4	34
76	Cost-effectiveness of Screening for Chronic Hepatitis C Infection in the United States. <i>Clinical Infectious Diseases</i> , 2013, 56, 1382-1393.	2.9	80
77	Combination Therapy With Telaprevir for Chronic Hepatitis C Virus Genotype 1 Infection in Patients With HIV. <i>Annals of Internal Medicine</i> , 2013, 159, 86-96.	2.0	179
78	Therapeutic Approach to the Treatment-Naive Patient With Hepatitis C Virus Genotype 1 Infection: A Step-by-Step Approach. <i>Clinical Infectious Diseases</i> , 2012, 55, 1236-1241.	2.9	4
79	Impact of Peginterferon Alpha and Ribavirin Treatment on Lipid Profiles and Insulin Resistance in Hepatitis C Virus/HIV-Coinfected Persons: The AIDS Clinical Trials Group A5178 Study. <i>Clinical Infectious Diseases</i> , 2012, 55, 631-638.	2.9	14
80	Extended Therapy With Pegylated Interferon and Weight-Based Ribavirin for HCV-HIV Coinfected Patients. <i>HIV Clinical Trials</i> , 2012, 13, 70-82.	2.0	11
81	Protective role of humoral immune responses during an outbreak of hepatitis E in Egypt. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2012, 106, 613-618.	0.7	30
82	Hepatitis C and HIV Co-Infection: New Drugs in Practice and in the Pipeline. <i>Current HIV/AIDS Reports</i> , 2012, 9, 231-237.	1.1	10
83	Low-level HIV infection of hepatocytes. <i>Virology Journal</i> , 2012, 9, 157.	1.4	44
84	Analysis of a non-structural gene reveals evidence of possible hepatitis C virus (HCV) compartmentalization. <i>Journal of Medical Virology</i> , 2012, 84, 242-252.	2.5	12
85	Managing adverse effects and complications in completing treatment for hepatitis C virus infection. <i>Topics in Antiviral Medicine</i> , 2012, 20, 125-8.	0.1	11
86	Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection. <i>New England Journal of Medicine</i> , 2011, 365, 1014-1024.	13.9	716
87	IL28B Alleles Exert an Additive Dose Effect When Applied to HCV-HIV Coinfected Persons Undergoing Peginterferon and Ribavirin Therapy. <i>PLoS ONE</i> , 2011, 6, e25753.	1.1	19
88	HIV/hepatitis C coinfection natural history and disease progression. <i>Current Opinion in HIV and AIDS</i> , 2011, 6, 478-482.	1.5	154
89	Hepatitis C virus infection in USA: an estimate of true prevalence. <i>Liver International</i> , 2011, 31, 1090-1101.	1.9	355
90	Liver Transplantation Trends in the HIV Population. <i>Digestive Diseases and Sciences</i> , 2011, 56, 3393-3398.	1.1	16

#	ARTICLE	IF	CITATIONS
91	Challenges and opportunities for hepatitis C drug development in HIVâ€“hepatitis C virus-co-infected patients. <i>Aids</i> , 2011, 25, 2197-2208.	1.0	33
92	Advanced liver disease: what every hepatitis C virus treater should know. <i>Topics in Antiviral Medicine</i> , 2011, 19, 121-5.	0.1	11
93	Sustained Long-Term Antiviral Maintenance Therapy in HCV/HIV-Coinfected Patients (SLAM-C). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 55, 597-605.	0.9	26
94	Occult Hepatitis B: Clinical Implications and Treatment Decisions. <i>Digestive Diseases and Sciences</i> , 2010, 55, 3328-3335.	1.1	55
95	Thymosin Î± 1 for treatment of hepatitis C virus: promise and proof. <i>Annals of the New York Academy of Sciences</i> , 2010, 1194, 136-140.	1.8	11
96	Variability of the Polymerase Gene (NS5B) in Hepatitis C Virus-Infected Women. <i>Journal of Clinical Microbiology</i> , 2010, 48, 4256-4259.	1.8	12
97	Hepatitis C Virus (HCV) Quasispecies Complexity and Selection in HCV/HIVâ€“Coinfected Subjects Treated with Interferonâ€“Based Regimens. <i>Journal of Infectious Diseases</i> , 2010, 201, 100127142343070-000.	1.9	17
98	Hepatitis E Virus Antibodies in Patients with Chronic Liver Disease. <i>Emerging Infectious Diseases</i> , 2009, 15, 479-481.	2.0	33
99	Improving Noninvasive Methods of Assessing Liver Fibrosis in Patients With Hepatitis C Virus/Human Immunodeficiency Virus Co-infection. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 471-480.e2.	2.4	17
100	Acute hepatitis C virus infection: A chronic problem. <i>Hepatology</i> , 2008, 47, 321-331.	3.6	102
101	Liver Biopsy in Cirrhotic Patients. <i>American Journal of Gastroenterology</i> , 2007, 102, 789-793.	0.2	50
102	New paradigms in the management of hepatitis C virus co-infections. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2007, 4, S10-S16.	1.7	2
103	The Prevalence and Significance of Occult Hepatitis B Virus in a Prospective Cohort of HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 44, 309-314.	0.9	63
104	Viral Factors Associated with Cytokine Expression During HCV/HIV Co-Infection. <i>Journal of Interferon and Cytokine Research</i> , 2007, 27, 263-270.	0.5	9
105	HIV and liver disease forum: Conference proceedings. <i>Hepatology</i> , 2007, 45, 1566-1577.	3.6	32
106	Development of novel agents for the treatment of chronic hepatitis C infection: Summary of the FDA Antiviral Products Advisory Committee recommendations. <i>Hepatology</i> , 2007, 46, 2014-2020.	3.6	23
107	Efficacy of inactivated hepatitis A vaccine in HIV-infected patients: a hierarchical bayesian meta-analysis. <i>Vaccine</i> , 2006, 24, 272-279.	1.7	54
108	Relationships between cellular immune responses and treatment outcomes with interferon and ribavirin in HIV/hepatitis C virus co-infection. <i>Aids</i> , 2006, 20, 345-351.	1.0	14

#	ARTICLE	IF	CITATIONS
109	Health Values of Patients Coinfected With HIV/Hepatitis C. <i>Medical Care</i> , 2006, 44, 158-166.	1.1	31
110	The clinical and physiological spectrum of interferon-alpha induced thyroiditis: Toward a new classification. <i>Hepatology</i> , 2006, 43, 661-672.	3.6	172
111	Extrahepatic replication of HCV: Insights into clinical manifestations and biological consequences. <i>Hepatology</i> , 2006, 44, 15-22.	3.6	171
112	HCV kinetics, quasispecies, and clearance in treated HCV-infected and HCV/HIV-1-coinfected patients with hemophilia. <i>Hepatology</i> , 2006, 44, 1146-1157.	3.6	32
113	Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. <i>Hepatology</i> , 2006, 44, 1110-1116.	3.6	178
114	Antigen-specific immune responses and liver histology in HIV and hepatitis C coinfection. <i>Aids</i> , 2005, 19, 767-773.	1.0	30
115	HCV quasispecies evolution: association with progression to end-stage liver disease in hemophiliacs infected with HCV or HCV/HIV. <i>Blood</i> , 2005, 105, 533-541.	0.6	51
116	Hepatitis C Virus in patients with inherited bleeding disorders. <i>Current Hepatitis Reports</i> , 2005, 4, 87-91.	0.3	0
117	Liver Injury and Changes in Hepatitis C Virus (HCV) RNA Load Associated with Protease Inhibitor-Based Antiretroviral Therapy for Treatment-Naive HCV-HIV-Coinfected Patients: Lopinavir-Ritonavir versus Nelfinavir. <i>Clinical Infectious Diseases</i> , 2005, 41, 1186-1195.	2.9	38
118	Clinical Trials of Treatment for Hepatitis C Virus Infection in HIV-Infected Patients: Past, Present, and Future. <i>Clinical Infectious Diseases</i> , 2005, 41, S63-S68.	2.9	10
119	Treatment of Hepatitis C Virus and Human Immunodeficiency Virus Co-infection. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, S118-S121.	2.4	4
120	Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients. <i>Gastroenterology</i> , 2005, 128, 313-327.	0.6	97
121	Treatment of Hepatitis C Virus/HIV Coinfection. <i>Clinics in Liver Disease</i> , 2005, 9, 525-533.	1.0	1
122	Nucleoside Analogues and Mitochondrial Toxicity. <i>Clinical Infectious Diseases</i> , 2004, 38, e79-e80.	2.9	114
123	Health Values of Patients With Chronic Hepatitis C Infection. <i>Archives of Internal Medicine</i> , 2004, 164, 2377.	4.3	53
124	Hepatitis C Virus (HCV) Diversity in HIV-HCV-Coinfected Subjects Initiating Highly Active Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2004, 189, 1472-1481.	1.9	35
125	Complexity and Diversity of Hepatitis C Virus RNA in African Americans and Whites: Analysis of the Envelope-Coding Domain. <i>Journal of Infectious Diseases</i> , 2004, 190, 511-514.	1.9	9
126	Comparison of HCV-specific intrahepatic CD4+ T cells in HIV/HCV versus HCV. <i>Hepatology</i> , 2004, 40, 125-132.	3.6	62

#	ARTICLE	IF	CITATIONS
127	Peginterferon Alfa-2a plus Ribavirin versus Interferon Alfa-2a plus Ribavirin for Chronic Hepatitis C in HIV-Coinfected Persons. <i>New England Journal of Medicine</i> , 2004, 351, 451-459.	13.9	856
128	Occult Hepatitis B in HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2004, 36, 869-875.	0.9	122
129	HCV and HIV: a tale of two viruses. <i>Reviews in Gastroenterological Disorders</i> , 2004, 4 Suppl 1, S48-54.	0.6	6
130	Implications of Peginterferon Use in Special Populations Infected with HCV. <i>Seminars in Liver Disease</i> , 2003, 23, 047-052.	1.8	4
131	Hepatitis C Virus Prevalence among Patients Infected with Human Immunodeficiency Virus: A Cross-Sectional Analysis of the US Adult AIDS Clinical Trials Group. <i>Clinical Infectious Diseases</i> , 2002, 34, 831-837.	2.9	678
132	Comparison of Methodologies for Quantification of Hepatitis C Virus (HCV) RNA in Patients Coinfected with HCV and Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2002, 35, 482-487.	2.9	29
133	Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects. <i>Aids</i> , 2002, 16, 1915-1923.	1.0	146
134	Diagnosis and management of the HCV/HIV-coinfected patient. <i>AIDS Clinical Care</i> , 2002, 14, 39-43, 48.	0.2	4
135	End-stage liver disease in persons with hemophilia and transfusion-associated infections. <i>Blood</i> , 2002, 100, 1584-9.	0.6	130
136	Prevalence and genotypic variability of TTV in HIV-infected patients. <i>Digestive Diseases and Sciences</i> , 2001, 46, 2401-2407.	1.1	17
137	Second opinion pathology in liver biopsy interpretation. <i>American Journal of Gastroenterology</i> , 2001, 96, 3158-3164.	0.2	43
138	Lack of Association of Hepatitis C Virus Load and Genotype with Risk of End-Stage Liver Disease in Patients with Human Immunodeficiency Virus Coinfection. <i>Journal of Infectious Diseases</i> , 2001, 184, 1202-1205.	1.9	38
139	Chronic Active Hepatitis B Exacerbations in Human Immunodeficiency Virus-Infected Patients Following Development of Resistance to or Withdrawal of Lamivudine. <i>Clinical Infectious Diseases</i> , 1999, 28, 1032-1035.	2.9	168
140	Cytokine Response to BCG Infection in Alcohol-Fed Mice. <i>Alcohol</i> , 1999, 19, 57-63.	0.8	13
141	Hepatitis cRNA quasispecies complexity in patients with alcoholic liver disease. <i>Hepatology</i> , 1999, 30, 265-270.	3.6	45
142	Rimantadine for treatment of hepatitis C infection in liver transplant recipients. <i>Liver Transplantation</i> , 1999, 5, 25-28.	1.9	6
143	Combination therapy with thymosin α 1 and interferon for the treatment of chronic hepatitis C infection: A randomized, placebo-controlled double-blind trial. <i>Hepatology</i> , 1998, 27, 1128-1135.	3.6	82